

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11. (Cancelled)

12. (New) A method for treating or preventing a major depression and/or treating a wake-sleep cycle disorder, comprising

administering to a subject in need thereof a pharmaceutical composition comprising a compound with formula (I) or a pharmaceutically acceptable salt thereof:



wherein the hydrogen atom in position 3 and the hydrogen atom in position 16 are trans, and the hydroxyl radical in position 14 in an α or β form.

13. (New) The method of claim 12, wherein the subject is partially or totally resistant to classical antidepressants.

14. (New) The method of claim 12, the depression is a bipolar depression according to DSM IV classification.

15. (New) The method of claim 14, wherein the bipolar type depression is a major recurrent depressive disorder (MRDD).

16. (New) The method of claim 12, wherein the subject is suffering from the major depression and is resistant to a classical antidepressant treatment and wherein said administering makes the subject sensitive to the classical antidepressant treatment.

17. (New) The method of claim 12, wherein said wake-sleep cycle disorder is selected from the group consisting of narcolepsy, hypersomnia and a chronic hypo-arousal condition.
18. (New) The method of claim 12, wherein the compound with formula (I) or one of its pharmaceutically acceptable salts is in the form of a racemic or an optically active mix.
19. (New) The method of claim 12, wherein the compound with formula (I) or one of its pharmaceutically acceptable salts is selected from:
- a) (3 α) (\pm) 14,15-dihydro 20,21-dinoreburnamenin 14-ol; and
 - b) (16 α) (\pm) 14,15-dihydro 20,21-dinoreburnamenin 14-ol,
- and wherein (+) and (-) diastereoisomers are or are not present in the compound in an equimolar proportion.
20. (New) The method of claim 12, wherein the compound with formula (I) or one of its pharmaceutically acceptable salts is selected from the group consisting of
- a) (3 α , 14 α) 14,15-dihydro 20,21-dinoreburnamenin 14-ol;
 - b) (3 α , 14 β) 14,15-dihydro 20,21-dinoreburnamenin 14-ol;
 - c) (14 α , 16 α) 14,15-dihydro 20,21-dinoreburnamenin 14-ol; and
 - d) (14 β , 16 α) 14,15-dihydro 20,21-dinoreburnamenin 14-ol.
21. (New) The method of claim 12, wherein said administering is performed orally, intravenously, or by an intraperitoneal or intramuscular method.
22. (New) The method of claim 12, wherein said administering comprises administering a daily dose from 20 to 60 mg of the compound with formula (I) or a pharmaceutically acceptable salt thereof.